Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study
This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.
Authors
- Francesco Pugliese (ORCID: https://orcid.org/0000-0002-8076-1250)
- Ippolita Zaza
- Maria Rita Carriero (ORCID: https://orcid.org/0000-0002-9197-5879)
- Luciana Pierro
- Vincenzo Patella (ORCID: https://orcid.org/0000-0001-5640-6446)
- Tiziana Peduto
- Massimo Triggiani (ORCID: https://orcid.org/0000-0001-7318-2093)
- Carmen Silvia Fiorella
- S. Pellè
- Antonio Giuliani (ORCID: https://orcid.org/0000-0002-7056-7155)
- Genoveffa Scotto Di Luzio
- Marina Castriota
- Pietro Morrone
- Pierfrancesco De Giacomo
- Eustachio Nettis (ORCID: https://orcid.org/0000-0003-1383-105X)
- Isabella Carrieri
- Giuseppe Fabrizio Amoruso
- Mattia Cristallo (ORCID: https://orcid.org/0009-0002-8055-5892)
Institutions
- University of Salerno (IT)
- Casa Sollievo della Sofferenza (IT)
- Accademia di Belle Arti di Lecce (IT)
- Istituto Nazionale di Fisica Nucleare, Sezione di Lecce (IT)
- Innovation Engineering (Italy) (IT)
- Azienda Ospedaliera di Cosenza (IT)
- Istituto S.Anna Crotone (IT)
- Radiation Oncology Institute (US)
- Istituto Oncologico Romagnolo (IT)
- Azienda Ospedaliera Pugliese Ciaccio (IT)
- Ospedale Sant'Anna (IT)
- University of Bari Aldo Moro (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Italian Journal of Dermatology and Venereology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.23736/s2784-8671.25.08228-3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00